CClinicalTrials.gg
CompletedNCT01905449Updated Apr 3, 2020

Ultrasound Biofeedback for Speech Sound Disorders

A Phase 1 interventional study of Ultrasound visual feedback in Speech Sound Disorders, sponsored by Yale University. Completed at 1 site in United States. Open to participants aged 8 Years to 50 Years. Per ClinicalTrials.gov, last updated 2020-04-03.

Sponsored by Yale University · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
35
Allocation
Non-randomized
Ages
8 Years to 50 Years
Sex
All
01

Study summary

Children with speech sound disorders will receive speech therapy using real-time images of the tongue from ultrasound. These images will be used to cue the child to change the tongue position when producing speech sounds.

02

Conditions studied

  • Speech Sound Disorders

Browse trials for

03

In context

Speech Sound Disorder

42 studies on the registry are indexed under Speech Sound Disorder; 16 are open to participants now.

This study's enrollment of 35 is close to the median of 35 across 37 interventional studies indexed under Speech Sound Disorder.

Browse Speech Sound Disorder studies →

Lead sponsor

Yale University is the lead sponsor of 1,724 studies on the registry; 298 are open to participants now.

Of its 210 completed or terminated interventional studies of FDA-regulated products, 126 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
8 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Participants must be native English-speaking children with no known hearing or vision deficits. Participants must be within the specified age range and have been identified as having speech production difficulties by a local speech-language therapist.

Exclusion criteria

Exclusion Criteria:

  • Participants will be excluded if there is a history of oral structural impairment (e.g., cleft palate), hearing or vision impairment, history of neurological impairment or injury, developmental disabilities such as Down Syndrome or Autism, or intellectual disability.

During initial testing, participants must score below a standard score of 75 on the Goldman-Fristoe Test of Articulation-2 and also score below 20% accurate on a probe list of words assessing accuracy of the /r/ sound

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Ultrasound plus prosodic cues

    One sound in error is treated with ultrasound visual feedback while also cueing prosodic variation (7 one-hour sessions). Another sound in error is treated with the ultrasound visual feedback with no prosodic variation (7 one-hour sessions). Prosodic variations are cues to coordinate production of the target sound with intonation patterns such as questions (rising intonations), commands (loud/emphatic), or statements (neutral)

    Behavioral: Ultrasound visual feedback

  • Experimental
    Ultrasound vs Traditional treatment

    One sound in errors is treated with ultrasound visual feedback for approximately half of each session and traditional treatment for half of the session (7 one-hour sessions). Another sound in error is treated with no ultrasound visual feedback, using traditional treatment for the entire session (7 one-hour sessions). These traditional cues include verbal instructions on how to move the tongue to achieve a particular speech sound.

    Behavioral: Ultrasound visual feedback

Interventions

  • BehavioralUltrasound visual feedback

    Real-time visual displays of the tongue are used to cue participants to modify the tongue position/shape as they articulate speech sounds

06

What researchers measure

Primary outcomes

  1. Percent correct for target speech sound

    Time frame: Change in accuracy after 7 one-hour treatment sessions (3.5 weeks), and after 14 one-hour treatment sessions (7 weeks)

07

Study locations

1 site
  • Haskins Laboratories
    New Haven, Connecticut 06511, United States
08

References and documents

Related links

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 3, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01905449
Lead sponsor
Yale University
Responsible party
Sponsor
First posted
Jul 23, 2013
Start date
May 2013
Primary completion
Jul 2016
Completion
Jul 2016
Last update
Apr 3, 2020

Study contacts

Jonathan Preston, PhD
principal investigator · Haskins Laboratories

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion